Duvortuxizumab
Duvortuxizumab
Duvortuxizumab (pronunciation: du-vor-tux-iz-u-mab) is a monoclonal antibody designed for the treatment of cancer. It is currently under investigation in clinical trials for its potential use in various types of cancer, including leukemia and lymphoma.
Etymology
The name "Duvortuxizumab" is derived from the International Nonproprietary Names (INN), where "zu" denotes humanized antibody, "tuxi" refers to the targeted antigen (CD19 in this case), and "mab" is the suffix for monoclonal antibodies.
Mechanism of Action
Duvortuxizumab works by binding to the CD19 antigen, a protein found on the surface of B-cells, including malignant B-cells in leukemia and lymphoma. This binding triggers an immune response that leads to the destruction of the cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- CD19 antigen: A protein found on the surface of B-cells that is often targeted in cancer treatments.
- B-cells: A type of white blood cell that is vital to the body's immune response.
- Leukemia: A type of cancer that affects the blood and bone marrow.
- Lymphoma: A type of cancer that begins in the lymphatic system.
External links
- Medical encyclopedia article on Duvortuxizumab
- Wikipedia's article - Duvortuxizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski